Medxtractor Looks to Transform Mobile Health with Machine-Learning
Ryan Allway
May 26th, 2021
Psychedelics, Top Story
Machine-Learning (“ML”) (sometimes referred to as artificial intelligence or “AI”) has experienced a renaissance over the past five years thanks to a combination of big data, fast processors, and new algorithms. ML is all around us; from stock trading to autonomous vehicles, ML is already transforming a wide range of industries by finding patterns in massive datasets and delivering actionable intelligence.
Medxtractor Corp. (CSE: MXT) (OTC: MXTTF) is leveraging ML, through its SHAMAN program, to predict probable mental illnesses, and the potential effects of various drugs, including psychedelics, on those illnesses. SHAMAN is a diagnostic tool with an over-arching goal of reducing misdiagnosis rates to increase the efficiency of the overall health system.
Let’s take a look at why improved diagnostics are necessary in mental health and how SHAMAN is well-positioned to address the industry’s shortcomings through ML.
Misdiagnosis in Mental Health
Misdiagnosis can happen with any medical conditions but, given our lack of visibility into the human brain, it’s especially common in mental health. For example, Johns Hopkins found that 60% of people in a non-hospital setting were misdiagnosed with major depression. Other studies have shown that bipolar disorder is similarly incorrectly diagnosed in many cases.
These misdiagnoses can be confusing to patients, but few question the judgment of their clinician. When the course of treatment doesn’t work, patients may feel distraught and breakdowns in communication are common. Incorrect medications can lead to unnecessary side effects while the true mental health condition may worsen.
While these misdiagnoses can be the result of masking symptoms or multiple diagnoses, often it is a lack of data and time that is the true cause. For instance, a person with borderline personality disorder might be incorrectly diagnosed with bipolar disorder due to their intense emotions; and without adequate data and time to fully analyze the situation the wrong drugs may be prescribed.
SHAMAN’s Novel Approach
Mental health conditions are difficult to diagnose because there aren’t any reliable diagnostic tests that doctors can run. While an X-ray can diagnose a broken bone or a blood test can show an infection, modern medicine hasn’t found a definitive way to correlate brain scans and other data with mental health disorders, which means doctors often need to rely on patient testimony.
Medxtractor developed SHAMAN to create a fast and deep diagnostic tool. Armed with brain wave data, factual biometric records, and proprietary algorithms, the company developed an ML-augmented system, called SHAMAN, to process large amounts of data and find patterns in the data, enabling high-probability, predictive diagnoses of mental health conditions. Even medical specialists are unable to correlate the massive number of calculations that are routine for machine learning systems. Underlying SHAMAN is the Reference Database, a collection of tightly-controlled, proprietary biometric/EEG records that forms the “memory” of the ML system.
The company believes that the technology could play an important role alongside psychedelics in revolutionizing mental health. In combination with more precise diagnoses, psychedelics promise far fewer side effects and greater efficacy than many conventional drugs for the treatment of mental health conditions.
Click here to receive an investor presentation and corporate updates
And there’s more…
YMI (why-am-I) is a consumer mHealth application that uses the same Reference Database as SHAMAN. YMI is designed to predict an individual’s probable health trajectory from current age to old age. This includes not only probable illness development but also a time frame for when an illness may develop and how lifestyle changes may affect the trajectory.
Massive Market Potential
The healthcare industry is known for its problematic legacy infrastructure and procedures that are now being replaced with mobile health or mHealth initiatives. SHAMAN is an mHealth application. With the growing popularity of Apple Watches, FitBits, and other wearables, the healthcare industry is recognizing people’s increasing proactive health interest. Just look at these numbers:
According to Grandview Research, the U.S. mHealth market could reach $166 billion by 2028, with apps far outpacing the growth of wearables. Diagnostics are expected to register the highest growth rate over the forecast period—an area where Medxtractor’s SHAMAN is targeting a key role.
Looking Ahead
Medxtractor Corp. (CSE: MXT) (OTC: MXTTF) is developing SHAMAN and YMI to address the needs of the increasingly health-conscious population. The Reference Database is growing daily and is expected to provide the foundation for shareholder value going forward.
SHAMAN’s potential could also extend well beyond mental health diagnoses. Using the same core problem-solving methodology, the company believes that the technology could be applicable across multiple verticals both in healthcare and beyond.
Click here to receive an investor presentation and corporate updates
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
PotBotics is a leading data aggregation and technology company focused on the global medical cannabis market.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
